Chronic Severe Uveitis

Bodaghi, Bahram; Cassoux, Nathalie; Wechsler, B.; Hannouche, D; Fardeau, Christine; Papo, Thomas; Huong, D. Lê Thi; Piette, Jean‐Charles; LeHoang, Phuc

doi:10.1097/00005792-200107000-00005

Cited by 232 publications

(63 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estimates of the proportion of bilateral cases from studies of uveitis patients in tertiary centres in the UK and Europe range from 41% to 67%. 11,[16][17][18] Each of these centres included patients with both anterior and posterior segment-involving uveitis. Three of the authors (AD, IP and FQ) provided clinical advice throughout, hereafter referred to as clinical advisors to the Assessment Group (AG).…”

Section: Aetiology Pathology and Prognosismentioning

confidence: 99%

“…3,14 The mean age at presentation for patients with all types of uveitis attending tertiary centres has been reported to range from 35 to 48 years across studies in the UK, 11,18 the Netherlands 15 and France. 16 There is extensive variation in the causes of uveitis worldwide, genetic factors and environmental features contributing significantly to its pathology. 14 Whereas infectious uveitis is frequently seen in developing countries, idiopathic non-infectious uveitis is more common in most of the developed world, including England.…”

Section: Aetiology Pathology and Prognosismentioning

confidence: 99%

“…Treatment failure: HURON trial Treatment failure in the HURON trial 48 was defined as a VH grade increase of ≥ 1 unit at weeks 3-8 or a VH of ≥ +1.5 at weeks [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. No data were reported in the journal article, 48 company submission 43 or clinical study report, 71 but a statistically significant difference between the DEX 700 arm and the sham arm (p < 0.001) was noted.…”

Section: Treatment Failurementioning

confidence: 99%

See 2 more Smart Citations

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Fahd Quhill has received personal fees from Allergan for participation in medical education and training, and has participated in advisory boards given his clinical expertise in the role of steroids in diabetic macular oedema. He has also received support from Allergan to attend international conferences.Published November 2017 DOI: 10.3310/hta21680 This report should be referenced as follows: This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 15/64/07. The protocol was agreed in June 2016. The assessment report began editorial review in December 2016 and was accepted for publication in May 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expre...

show abstract

Section: Aetiology Pathology and Prognosismentioning

confidence: 99%

Section: Aetiology Pathology and Prognosismentioning

confidence: 99%

Section: Treatment Failurementioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Uveitis accounts for 5 to 20% of legal blindness in both the United States and Europe and perhaps for as much as 25% of blindness in the developing world (1,2). Infectious uveitis is more common in the developing world, accounting for 30 to 50% of all uveitis cases (3,4).…”

mentioning

confidence: 99%

“…The most common infectious uveitis etiologies include toxoplasmosis, tuberculosis, onchocerciasis, cysticercosis, leprosy, and leptospirosis (2). In developed countries, infectious uveitis, mainly due to herpesvirus infection and toxoplasmosis, accounts for a much smaller number of cases, with other causes like tuberculosis and syphilis being even less common (1,5). The most common causes of noninfectious uveitis include Fuchs heterochromic iridocyclitis, HLA-B27-associated uveitis, intermediate uveitis, birdshot chorioretinopathy, sympathetic ophthalmia, sarcoidosis, multifocal choroiditis, VogtKoyanagi-Harada (VKH) syndrome, serpiginous choroiditis, and Behçet's disease.…”

mentioning

confidence: 99%

Intraocular Levels of Interleukin 17A (IL-17A) and IL-10 as Respective Determinant Markers of Toxoplasmosis and Viral Uveitis

Sauer

Villard

Creuzot‐Garcher

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

e Uveitis is a potentially blinding inflammatory disease. Thirty to 50% of uveitis cases are considered idiopathic. The present study sought to determine the intraocular cytokine patterns in the different etiological types of uveitis in order to better understand their immunological regulation and to determine whether the cytokine pattern may be a useful diagnostic tool. From a multicenter institutional prospective study, the clinical and biological data from patients with uveitis of various etiologies, determined after a complete workup, were compared with those from a control group of cataract patients. A multiplex assay was used to assess the profiles of 27 cytokines and chemokines in aqueous humor samples from these patients. In total, 62 patients with infectious or noninfectious uveitis and 88 controls were included. After a complete workup, the cause of uveitis remained unknown in 25 patients (40% idiopathic uveitis). Interleukin 1␤ (IL-1␤) levels were markedly increased in viral uveitis, as were IL-10 levels, whereas IL-17A levels were augmented in toxoplasmic uveitis. Based on the cytokine pattern, the patients were reassigned to specific groups. At the end of the study, the diagnosis of idiopathic uveitis was still valid in only 11 patients (18%). The observation that some markers are specific to certain diseases enables a better understanding of the disease pathogenesis and paves the way for new diagnostic methods aimed to identify inflammatory markers, which may perhaps be targeted by therapy.

show abstract

Prevalence of Noninfectious Uveitis in the United States

et al. 2016

View full text Add to dashboard Cite

IMPORTANCE Noninfectious uveitis (NIU) is a collection of intraocular inflammatory disorders that may be associated with significant visual impairment. To our knowledge, few studies have investigated NIU prevalence overall or stratified by inflammation location, severity, presence of systemic conditions, age, or sex. OBJECTIVE To estimate NIU prevalence using a large, retrospective, administrative claims database. DESIGN, SETTING, AND PARTICIPANTS This analysis used the OptumHealth Reporting and Insights database to estimate 2012 NIU prevalence. Analysis was conducted in September 2016. The large administrative insurance claims database includes 14 million privately insured individuals in 69 self-insured companies spanning diverse industries. Included in the study were patients with NIU with 2 or more uveitis diagnoses on separate days in 2012 and continuous enrollment in a health plan for all of 2012 and categorized by inflammation site. MAIN OUTCOMES AND MEASURES We estimated overall NIU prevalence by inflammation site, severity, sex, and age. Patients with anterior NIU were categorized by the presence of systemic conditions. RESULTS Of the approximately 4 million eligible adult patients, approximately 2.1 million were women, and of the 932 260 children, 475 481 were boys. The adult prevalence of NIU was 121 cases per 100 000 persons (95% CI, 117.5-124.3). The pediatric NIU prevalence was 29 cases per 100 000 (95% CI, 26.1-33.2). Anterior NIU accounted for 81% (3904 cases) of adult NIU cases (98 per 100 000; 95% CI, 94.7-100.9) and 75% (207 cases) of pediatric NIU cases (22 per 100 000; 95% CI, 19.3-25.4). The prevalences of noninfectious intermediate, posterior, and panuveitis were, for adults, 1 (95% CI, 0.8-1.5), 10 (95% CI, 9.4-11.5), and 12 (95% CI, 10.6-12.7) per 100 000, respectively, and for pediatric patients, 0 (95% CI, 0.1-1.1), 3 (95% CI, 1.8-4.1), and 4 (95% CI, 2.9-5.6) per 100 000, respectively. The prevalence of NIU increased with age and was higher among adult females than males. Application of these estimates to the US population suggests that NIU affected approximately 298 801 American adults (95% CI, 290 512-307 324) and 21 879 children (95% CI, 19 360-24 626) in 2015. CONCLUSIONS AND RELEVANCE The estimated prevalence of NIU was 121 cases per 100 000 for adults (95% CI, 117.5-124.3) and 29 per 100 000 for children (95% CI, 26.1-33.2). Prevalence was estimated using administrative claims from a commercially insured population, which may have a different prevalence than other segments of the US population. A better understanding of the prevalence of NIU will help to determine the number of patients affected.

show abstract

Chronic Severe Uveitis

Cited by 232 publications

References 40 publications

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Intraocular Levels of Interleukin 17A (IL-17A) and IL-10 as Respective Determinant Markers of Toxoplasmosis and Viral Uveitis

Prevalence of Noninfectious Uveitis in the United States

Contact Info

Product

Resources

About